Company Description
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases.
The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases.
Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs.
The company is headquartered in Alameda, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Nov 19, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Adam Mendelsohn |
Contact Details
Address: 1350 South Loop Road Alameda, California 94502 United States | |
| Phone | 415 506 8462 |
| Website | vivani.com |
Stock Details
| Ticker Symbol | VANI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001266806 |
| CUSIP Number | 92854B109 |
| ISIN Number | US92854B1098 |
| Employer ID | 02-0692322 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adam Mendelsohn Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Anthony Edward Baldor M.B.A. | Chief Financial Officer |
| Truc Le M.B.A. | Chief Operations Officer |
| Dr. Lisa E. Porter M.D. | Chief Medical Officer |
| Donald Dwyer M.B.A. | Chief Business Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2026 | 8-K | Current Report |
| May 13, 2026 | 10-Q | Quarterly Report |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 26, 2026 | 10-K | Annual Report |
| Jan 27, 2026 | 8-K | Current Report |
| Jan 27, 2026 | 424B5 | Filing |
| Nov 13, 2025 | 10-Q | Quarterly Report |